Oncotarget

Research Papers:

Mitochondrial oxidative phosphorylation controls cancer cell’s life and death decisions upon exposure to MAPK inhibitors

Paola Corazao-Rozas, Pierre Guerreschi, Fanny André, Pierre-Elliott Gabert, Steve Lancel, Salim Dekiouk, Delphine Fontaine, Meryem Tardivel, Ariel Savina, Bruno Quesnel, Laurent Mortier, Philippe Marchetti and Jérome Kluza _

PDF  |  HTML  |  Supplementary Files  |  Order a Reprint

Oncotarget. 2016; 7:39473-39485. https://doi.org/10.18632/oncotarget.7790

Metrics: PDF 1076 views  |   HTML 1135 views  |   ?  


Abstract

Paola Corazao-Rozas1,2,3,*, Pierre Guerreschi1,2,3,*, Fanny André1,2,3, Pierre-Elliott Gabert1,2,3, Steve Lancel4, Salim Dekiouk1,2,3, Delphine Fontaine1,2,3, Meryem Tardivel6, Ariel Savina7, Bruno Quesnel1,2,3, Laurent Mortier1,2,3, Philippe Marchetti1,2,3,5,#, Jérome Kluza1,2,3,#

1University Lille, Inserm, CHU Lille, UMR-S 1172 - JPArc - Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer, Lille, France

2Institut pour la Recherche sur le Cancer de Lille (IRCL), Lille, France

3SIRIC OncoLille, Lille, France

4University Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011- EGID, Lille, France

5Centre de Bio-Pathologie, Plate-forme de Biothérapie, Banque de Tissus, CHRU Lille, Lille, France

6Bioimaging Center, Lille Nord de France-Campus HU, Université de Lille 2, Lille, France

7Institut Roche, Boulogne-Billancourt, France

*These authors contributed equally to this work

#These authors shared equally co-ownership to this work

Correspondence to:

Jérome Kluza, email: jerome.kluza@inserm.fr

Philippe Marchetti, email: philippe.marchetti@inserm.fr

Keywords: vemurafenib, cobimetinib, BRAF, Ca2+ uptake, melanoma

Received: November 05, 2015     Accepted: February 05, 2016     Published: February 29, 2016

ABSTRACT

Although MAPK pathway inhibitors are becoming a promising anticancer strategy, they are insufficient to fully eliminate cancer cells and their long-term efficacy is strikingly limited in patients with BRAF-mutant melanomas. It is well established that BRAF inhibitors (BRAFi) hamper glucose uptake before the apparition of cell death. Here, we show that BRAFi induce an extensive restructuring of mitochondria including an increase in mitochondrial activity and biogenesis associated with mitochondrial network remodeling. Furthermore, we report a close interaction between ER and mitochondria in melanoma exposed to BRAFi. This physical connection facilitates mitochondrial Ca2+ uptake after its release from the ER. Interestingly, Mfn2 silencing disrupts the ER–mitochondria interface, intensifies ER stress and exacerbates ER stress-induced apoptosis in cells exposed to BRAFi in vitro and in vivo. This mitochondrial control of ER stress-mediated cell death is similar in both BRAF- and NRAS-mutant melanoma cells exposed to MEK inhibitors. This evidence reinforces the relevance in combining MAPK pathway inhibitors with mitochondriotropic drugs to improve targeted therapies.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 7790